 |
Previous Article | Next Article 
Volume 16, Number 22,
Issue of November 15, 1996
pp. 7331-7335
Copyright ©1996 Society for Neuroscience
The Sympathetic Nervous System Contributes to Capsaicin-Evoked
Mechanical Allodynia But Not Pinprick Hyperalgesia in Humans
Maywin Liu1, 3,
Mitchell
B. Max1,
Suzan Parada2,
Janet S. Rowan2, and
Gary J. Bennett1
1 Neurobiology and Anesthesiology Branch, National
Institute of Dental Research, and 2 Clinical Center
Nursing, National Institutes of Health, Bethesda, Maryland 20892, and 3 Department of Anesthesia, Hospital of the
University of Pennsylvania, Philadelphia, Pennsylvania 19104
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES
ABSTRACT
The contribution of the sympathetic nervous system (SNS) to
pain, mechanical allodynia (MA), and hyperalgesia in humans is
controversial. A clearer understanding is crucial to guide therapeutic
use of sympatholytic surgery, blocks, and drug treatments. In rats,
capsaicin-evoked MA, and to some extent, pinprick hyperalgesia (PPH),
can be blocked with -adrenoreceptor antagonists. In this study, we
examined the contribution of the SNS to MA and PPH in normal human
subjects by blocking -adrenoreceptors with intravenous
phentolamine.
In a double-blinded, placebo-controlled, crossover study, subjects were
given IV saline or phentolamine, 1 mg/kg over 20 min. Ten minutes after
the start of the infusion, subjects received 100 µg of intradermal
capsaicin on the foot dorsum with the temperature of the injected site
clamped at 36°C. The temperature of the uninjected foot was used to
monitor the degree of -adrenoreceptor blockade produced by
phentolamine. Ongoing pain and MA and PPH areas were measured every 5 min for 60 min.
A significantly greater increase in temperature on the uninjected foot
was seen during the phentolamine infusion compared with the saline
infusion, indicating -adrenergic blockade. Significantly less MA was
observed with the phentolamine infusion 10-25 min after capsaicin
injection than with the saline infusion. No significant differences in
ongoing pain or PPH areas were seen between the two infusions at any
time.
Our results suggest that capsaicin-evoked MA and PPH have different
mechanisms, with the SNS having a role in MA but not in PPH or ongoing
pain.
Key words:
sympathetic nervous system;
mechanical
allodynia;
mechanical hyperalgesia;
capsaicin;
phentolamine;
pain
INTRODUCTION
After some cases of nerve injury, pain phenomenon
such as mechanical allodynia (MA), pain caused by normally innocuous
stimuli) and pinprick hyperalgesia (PPH), greater pain than that
normally induced by a painful stimulus) are often seen within and
outside of the peripheral nerve territory of the injured area (Kelly,
1952 ; Dykes, 1984 ; Marchettini et al., 1992 ). The mechanisms of MA and
PPH are not completely understood. One explanation is that these
changes are caused by sensitization of secondary neurons of the CNS by
intense peripheral nociceptor input, resulting in abnormal processing
of painful and normally nonpainful stimuli. These neurons may require
continued peripheral input to sustain these changes (Levine et al.,
1985 ; LaMotte et al., 1991 ; Gracely et al., 1992 ). Animal data have
indicated that the sympathetic nervous system (SNS) may contribute to
this heightened peripheral input. In the normal, uninjured state,
somatosensory primary afferent nociceptors do not appear to have
sympathetic sensitivity. However, after injury, catecholamine
sensitivity is often seen (Sato and Perl, 1991 ). Neuromas proximal to
the site of injury develop ectopic discharges that increase with close
intra-arterial injection of catecholamines and with stimulation of the
sympathetic trunk (Wall and Gutnick, 1974 ; Korenman and Devor, 1981 ;
Jänig, 1990 ).
In addition to nerve injury, pain produced by direct chemical
activation of C-fibers with capsaicin, the purified active ingredient
of chili peppers, has been used as a model to study MA and PPH.
Capsaicin has been shown to cause MA and PPH, with symptoms similar to
those of nerve injury (Koltzenburg et al., 1992 ; Torebjörk et
al., 1992 ). In both the nerve injury and capsaicin animal models,
surgical and chemical sympathectomies and peripheral -adrenoreceptor
antagonists have relieved MA (Kim and Chung, 1991 ; Kinnman and Levine,
1995 ).
Patients with MA, PPH, and trophic changes possibly suggestive of
increased sympathetic tone often obtain relief after block of the
sympathetic innervation to the affected area (Loh and Nathan, 1978 ;
Raja et al., 1991 ). These patients are considered to have
``sympathetically maintained pain'' (SMP) (Roberts, 1986 ). Many of
these patients also obtain relief with the nonspecific -adrenergic
antagonist phentolamine and with regional sympatholytic treatment with
guanethidine (Loh and Nathan, 1978 ; Blanchard et al., 1990 ; Raja et
al., 1991 ). Phentolamine provides pain relief comparable with that seen
with local anesthetic block of the sympathetic ganglion (Raja et al.,
1991 ).
However, the importance of the SNS in sensory changes remains
controversial. Some investigators claim that the sensory changes
outside the territory of an injured nerve and the apparent relief with
sympathetic block are attributable to psychological factors (Verdugo
and Ochoa, 1994 ; Verdugo et al., 1994 ; Ochoa and Verdugo, 1995 ). An
experimental model of SMP in normal volunteers would facilitate
research into the sympathetic contribution to pain. In this study, we
examined the possible role of the SNS, specifically the -adrenergic
receptors, in the production of MA and PPH produced by capsaicin in
normal human volunteers.
MATERIALS AND METHODS
Healthy volunteers were entered into this double-blinded,
placebo-controlled, two-period crossover study. Because of the large
variability in responses to capsaicin (Liu et al., 1995a ; Park et al.,
1995 ), all subjects were screened for their MA response to intradermal
(ID) capsaicin before entry. Patients with MA responses 5 cm2 for at least 20 min advanced to the infusion portion of
the study.
During all experimental sessions, subjects were placed in the seated
position with their lower leg 135° to their thigh. We preferred
subjects to be in a sitting position, because we had used that position
in a previous study of MA and PPH on the forearm and foot dorsum and
found larger areas of MA and PPH on the foot dorsum (Liu et al.,
1995b ). In addition, we had observed lower cutaneous blood flow in the
foot dorsum with the foot dependent compared with the foot placed at
the same level as the legs, suggesting higher sympathetic tone in the
dependent position (Liu M, Max MB, Robinovitz E, Gracely RH, Bennett
GJ, unpublished observations). Subjects were asked to inform the
investigators whether they had any sensations of the leg ``falling
asleep.''
Because of the known temperature sensitivity of capsaicin-evoked
sensory changes (Koltzenburg et al., 1992 ; Liu et al., 1995a ), we
stabilized the skin temperature of the injection site on the dorsum of
the left foot at 36°C (range, 35.8-36.2°) using a
feed-back-controlled heat lamp with the thermistor placed 1 cm from the
injection site. Once the temperature was stable, 100 µg (10 µl) of
ID capsaicin (Fluka, Ronconocow, NY) in Tween 80 was injected into that
foot. Temperature was monitored in the uninjected right foot to assess
the effect of phentolamine on peripheral adrenoreceptors. Ongoing pain
was measured at the time of injection using a 0-100, 20 cm Visual
Analog Scale (VAS). Ongoing pain, MA, and PPH were measured every 5 min
after injection for a total of 60 min. MA was measured using a #2 flat
artist's brush moving along eight radial spokes, beginning in an area
with normal sensation ~8 cm from the injection site and moving toward
the site at a rate of 1 cm/sec, as described by Simone et al. (1989) .
To ensure beginning in an area of normal sensation, brush sensation of
the injected foot ~8 cm from the injection site was compared with the
brush sensation of the uninjected foot 5 min after injection. Subjects
were instructed to inform the investigator whether and when the
sensation changed to ``pain or discomfort.'' This spot was marked
lightly with a marking pen. PPH was assessed using a 3.8 cm safety pin
pressed lightly into the skin to cause a just barely visible
indentation. Testing began 8 cm from the injection site, comparing the
sensation with that of the uninjected foot to ensure that initial sites
of stimulation had normal pinprick sensation. Subjects did not observe
the sensory testing. Subjects were instructed to inform the
investigators when the pinprick sensation changed into ``something
more painful or a different type of pain.'' If the subjects answered
positively, he or she was asked to describe the sensation. This spot
was then marked with a marking pen. The marks for the areas of MA and
PPH were then transferred onto clear acetate sheets and connected to
form polygons.
All sensory testing was done by three nurse investigators. Subjects who
advanced to the phentolamine/placebo portion of the study had the same
nurse for all three sessions. Nurse investigators were thoroughly
trained in the brush and pin techniques before performing sensory
testing on any subjects, and all were observed to perform the testing
in a similar manner. Nurse investigators and the subjects were blinded
as to the infusion condition. The physician monitoring the vital signs
and temperature of the uninjected foot was not blinded but did not
participate in the sensory testing. Pulse-oximetry, blood pressure, and
ECG monitors were hidden from the view of the subjects and the nurses.
Subjects were questioned for presyncopal symptoms (light-headedness,
dizziness, nausea) 2 min before capsaicin injection and 30 sec and 5 min after injection during each session.
Subjects were randomly assigned to either of two possible treatments
orders: 1 mg/kg phentolamine (Ciba-Geigy, Summit, NJ) and saline or
saline and phentolamine. A 20 gauge intravenous catheter was placed
into a right antecubital vein, and a bolus of 1000 ml of saline given
over 30 min before the start of the phentolamine/placebo infusion as
prophylaxis against hypotension that might result from phentolamine.
Once the bolus was completed, the phentolamine/placebo solution (100 ml) was infused over 20 min with a 2 ml/kg/hr background infusion rate
of saline. Infusion sessions were all conducted in the afternoon.
Subjects were instructed to have both breakfast and lunch before the
sessions. Sessions, including the capsaicin screen, were separated by a
minimum of 1 week. The subject's surface anatomy (veins, nevi, scars,
etc.) was traced onto acetate sheets and the point of injection marked
on this sheet to ensure that areas used previously were not reinjected.
To keep injection sites relatively uniform, sites were chosen so that
they were 1-2 mm adjacent to veins on the mid-dorsum of the foot.
Continuous EKG and pulse-oximetry and intermittent blood pressure
readings (every 10 min before the start of the drug infusion, every 2 min during the infusion and the initial 15 min after the completion of
the infusion, and every 5 min 15 min after the end of the infusion)
were obtained throughout each infusion session. The skin temperature of
the left foot was stabilized, as described above. Temperature of the
uninjected foot was measured continuously with a contact thermistor to
assess presence of -adrenergic blockade. Ten minutes after the start
of the phentolamine/placebo infusion, the subject was given 100 µg of
ID capsaicin to the foot dorsum.
MA and PPH areas were obtained by copying the acetate sheets onto
standard photocopy paper, cutting out and weighing the obtained areas,
and comparing these weights with the weight of a known area.
Statistical analysis. Because preliminary analysis revealed
a non-Gaussian distribution, MA and PPH areas for the two treatments at
each time point were compared using the Wilcoxon signed rank test.
Ongoing pain was analyzed using ANOVA with repeated measures. Peak
temperature difference was analyzed using a t test. All
results are shown as mean ± SEM.
RESULTS
Twenty-three subjects were prescreened with capsaicin to obtain
the final sample size of 16. Six subjects had inadequate MA areas
during the screen, and one subject chose not to continue to the drug
portion of the study. During the screening session, subjects with MA
and PPH were asked to describe the sensation they had. MA was
consistently described as a burning or tenderness and PPH was described
as an initial increased sharpness followed by a burning sensation with
removal of the pin. The study population consisted of 3 women and 13 men whose ages ranged from 22 to 39 years.
All subjects reported high pain VAS 10 sec after capsaicin injection
during both the phentolamine and placebo infusions, 86.5 ± 1.2 versus 85.5 ± 1.2, respectively, on a scale of 100 (NS).
Significantly smaller MA areas were noted during the phentolamine
session as compared with the placebo session at each time point from 10 to 25 min after capsaicin administration (p < 0.05) (Fig. 1). No significant difference in ongoing VAS
pain scores were noted between the two sessions at any time point,
although there was a nonsignificant tendency for lower pain with
phentolamine (p > 0.3, ANOVA) (Fig.
2). There were no differences in PPH areas between the
two sessions at any time point (Fig. 3). No differences
in the descriptions of the PPH sensations were observed between the
saline and phentolamine infusions.
Fig. 1.
MA areas during the phentolamine (open
squares) and saline (filled diamonds)
infusions. Each point represents the mean areas of all 16 subjects at
that time point ± SEM. The vertical line at time ``0''
indicates the time of capsaicin injection. Phentolamine/saline
infusions were started at 10 min and completed by +10 min.
*p < 0.05, areas of significantly decreased MA
area during phentolamine infusion as compared with the saline infusion,
Wilcoxon signed rank test.
[View Larger Version of this Image (24K GIF file)]
Fig. 2.
Ongoing pain measured on a 20 cm VAS during the
phentolamine (open squares) and saline
(filled diamonds) infusions. Each point
represents the mean ratings for all 16 subjects at that time point ± SEM.
[View Larger Version of this Image (19K GIF file)]
Fig. 3.
PPH areas during the phentolamine (open
squares) and saline (filled diamonds)
infusions. Each point represents the mean areas of all 16 subjects at
that time point ± SEM.
[View Larger Version of this Image (18K GIF file)]
Higher temperatures were seen in the uninjected foot from the end of
the phentolamine infusion (10 min after capsaicin injection) to the end
of the session (Fig. 4). A mean peak increase (±SEM) in
the temperature of the uninjected foot (measured before the start of
the drug infusion to the peak temperature during the 60 min testing
interval) of 2.9 ± 0.6°C was seen in the phentolamine session
versus 0.6 ± 0.2°C in the placebo session
(p < 0.001), indicating presence of
-adrenergic blockade (Raja et al., 1991 , 1996 ). On average, maximal
temperature change was noted 15 min after the end of the infusion or 25 min after capsaicin injection (Fig. 4).
Fig. 4.
Skin temperatures. Mean temperature ± SEM
(°C) during the course of the study for the phentolamine (open
squares) and saline (filled diamonds)
infusions as measured on the uninjected foot.
[View Larger Version of this Image (22K GIF file)]
Vital signs remained stable through both infusions. Vasopressors were
not required by any subject for treatment of hypotension during either
infusion.
Unlike previous investigators (Raja et al., 1991 ), we did not use
-blockers to blunt any possible tachycardia. In three pilot
patients, we had administered the recommended intravenous 1 mg
propranolol just before phentolamine infusion. Two of the three
subjects developed near-syncopal symptoms consisting of complaints of
nausea and light-headedness accompanied by bradycardia and hypotension
~2-5 min after capsaicin injection. We thought that this resulted
from the blockade of hemodynamic compensatory mechanisms evoked by the
combination of phentolamine and propranolol with the subject in the
sitting position, causing unacceptable bradycardia and hypotension.
Based on these reactions, propranolol was not used in our study and the
prestudy saline bolus was increased from 500 to 1000 ml. No clinically
significant incidents of bradycardia or hypotension were seen after the
propranolol was discontinued. Although none of the subjects were
informed of the symptoms of -adrenoreceptor blockade, 13 of the 16 subjects reported nasal stuffiness during the phentolamine infusion.
DISCUSSION
Our results extend to humans the findings obtained by Kinnman and
Levine (1995) in rats. These investigators observed a complete or
nearly complete prevention of capsaicin-evoked MA by phentolamine and
by prazosin, a specific -1 adrenoreceptor antagonist. However, in
our experiments, MA was not completely blocked by phentolamine. The
discrepancy may be attributable to a species difference in the amount
of sympathetic tone in the extremities, which is likely to be greater
in humans because of the greater distance from the heart and
the species difference in the thermoregulatory role of cutaneous blood
flow (rats thermoregulate primarily by spreading saliva over their
fur). In addition, the dose of phentolamine that we used (1 mg/kg over
20 min) results in only partial blockade (~88%) (Raja et al.,
1994 ).
We observed a significant decrease in MA only during the period of
10-25 min after capsaicin injection. The lack of a significant effect
at the 5 min test point, when 75% of the phentolamine dose had been
delivered, may reflect an inadequate block. This is supported by the
temperature data (Fig. 4), which showed little of the expected
temperature increase at 5 min after capsaicin administration. The lack
of a phentolamine effect after 25 min may have been at least partly
attributable to the metabolism of phentolamine, the elimination
half-life of which is 19 min. The waning effect after 25 min was also
probably attributable to the natural time course of capsaicin-evoked
MA. As has been described previously, many subjects showed little MA 30 min after injection (Simone et al., 1989 ; LaMotte et al., 1991 ; Liu et
al., 1995a ; Park et al., 1995 ). The decrease in MA with phentolamine
observed in the present study is not attributable to a temperature
effect, because the site of capsaicin injection was kept at a fixed
temperature of 36°C, a temperature higher than the peak temperature
reached in the uninjected foot during the phentolamine session.
Although we cannot rule out the possibility that phentolamine-induced
nasal congestion unblinded the subjects and introduced self-report
bias, we would have expected such a bias to produce similar effects on
MA, PPH, and ongoing pain. Although the nurses doing the sensory
testing could also potentially introduce bias after hearing subjects
report this symptom, these clinicians had no investment in any
particular outcome of the study, particularly the complex set of
findings that we report.
The present data and the animal experiments of Kinnman and Levine
(1995) suggest that capsaicin-evoked MA is reduced by blockade of
sympathetic -adrenoreceptors. The mechanism of this effect is
unknown.
A CNS mechanism is unlikely, because Kinnman and Levine (1995) showed
that preganglionic sympathectomy has no effect on capsaicin-evoked MA.
With the high dose of phentolamine used in the present experiments, we
cannot exclude the possibility of a central effect of the drug.
However, one would expect that central -adrenoreceptor block would
increase pain via a reduction in the activity of the
descending pain-inhibitory noradrenergic pathway that terminates in the
spinal dorsal horn. Thus, it seems probable that the effects seen in
the present experiments, like those of Kinnman and Levine (1995) , are
attributable to an effect in the periphery. There are two possible
peripheral sites for an -adrenoreceptor effect on capsaicin-evoked
MA: A low-threshold mechanoreceptors (A LTMs) or C-fiber
nociceptors.
An effect on A LTMs is an unlikely explanation for our results. MA
is evoked by A LTM stimulation (Torebjörk et al., 1992 ; Sang
et al., 1996 ), and there is no reason to suspect that
-adrenoreceptor blockade has any effect on stimulus-evoked activity
in these afferents. Roberts (1986) has suggested that a tonic
sympathetically maintained A LTM input sustains the hyperalgesic and
allodynic sensations seen in nerve-injured patients. It is difficult to
imagine how such a mechanism might be relevant to the present case, in
which normal subjects exhibited phentolamine-blockable MA 10 min after
capsaicin injection.
If there is an -adrenoreceptor effect that is necessary for or
enhances the capsaicin-evoked C-nociceptor discharge, then
-adrenoreceptor blockade would prevent or reduce the amount of
central sensitization and thereby reduce the substrate for MA. However,
there is no direct evidence that an -adrenoreceptor action on
C-nociceptors modulates their activation by capsaicin. Capsaicin is an
inflammatory stimulus and inflammation sensitizes C-nociceptors and
``awakens'' normally silent ``sleepy'' C-nociceptors (Handwerker et
al., 1991 ; Davis et al., 1993 ; Sato et al., 1993 ; Schmidt et al.,
1995 ). If an -adrenoreceptor action is necessary for sensitization
or for awakening sleepy nociceptors, then phentolamine block might have
reduced the amount of C-nociceptor activity during at least the latter
stages of the postinjection interval. If this occurred, one would
expect phentolamine to blunt the perceived intensity of
capsaicin-evoked pain. Our results indicate a trend toward decreased
pain with phentolamine, but this did not reach statistical significance
(p > 0.3; Fig. 2).
Phentolamine had no effect on capsaicin-evoked PPH. Several lines of
evidence indicate that capsaicin-evoked MA and PPH are at least partly
independent phenomena. Capsaicin-evoked PPH is found in a distinctly
larger area than MA, and it lasts a much longer time (Simone et al.,
1989 ; LaMotte et al., 1991 ; Park et al., 1995 ). MA and PPH sensations
are distinctly different qualitatively: MA is felt as a burning pain or
a dysesthetic ``raw'' feeling like that of a sunburn; PPH is
initially a distinctly localized, sharp, pricking pain with an electric
shock-like component that evokes a flinch (M. Liu, unpublished
observations). The afferent input that evokes PPH is not known, but it
is likely to be A - and/or C-fiber nociceptors. This is
supported by a report of a patient with loss of A function and
preservation of A and C-fibers, showing that capsaicin produced
ongoing pain and PPH but not MA (Treede and Cole, 1993 ). It may be of
significance that trauma does not evoke -adrenergic sensitivity in
A afferents (Bossut and Perl, 1995 ).
It has been argued that the relief of neuropathic pain in patients
receiving sympathetic or -adrenoreceptor blockade is a placebo
response and, further, that this and other evidence indicate that many
patients diagnosed with SMP and related conditions suffer from a
disorder that is primarily or exclusively psychogenic (Verdugo and
Ochoa, 1994 ; Verdugo et al., 1994 ; Ochoa and Verdugo, 1995 ). The
results reported here cannot be explained in this way, because neither
the experimenters nor the subjects had any reason to believe that
phentolamine would affect MA but not PPH or ongoing pain.
The human capsaicin model may be useful for elucidating the mechanisms
by which sympathetic activity contributes to pain. MA and other
abnormal pain sensations are exacerbated by -adrenoreceptor agonists
(Drummond, 1995 ) and relieved by sympathetic nerve and
-adrenoreceptor blockade in patients and animals with painful
peripheral neuropathies (Bonica, 1990 ; Bennett and Roberts, 1996 ) and
in animal models of inflammation (Levine et al., 1985 , 1986 ; Hu and
Zhu, 1989 ; Sato et al., 1993 ). The sensory changes obtained with
capsaicin occur within minutes, and their mechanism may differ from
those occurring in some chronic SMP syndromes in which new
adrenoreceptor formation has been hypothesized. Although there may be
differences in the sympathetic efferent and adrenoreceptor contribution
to inflammatory, neuropathic, and capsaicin-evoked pain, our results
suggest that animal and human capsaicin models may be used in tandem to
work out the details of sympathetic interactions with each class of
primary afferent and secondary neurons. The resulting insights into
neural integration are likely to contribute to the understanding of
many pain conditions.
FOOTNOTES
Received June 10, 1996; revised Aug. 19, 1996; accepted Aug. 29, 1996.
We thank Elaine Robinovitz and Mary Wells for their help in conducting
this study, Dr. Robert Coghill for help with the statistics, and Drs.
Eli Eliav and Andrew Mannes for reviewing this manuscript.
Correspondence should be addressed to Dr. Mitchell B. Max, National
Institutes of Health, 9000 Rockville Pike, Building 10, Room 3C-405,
Bethesda, MD 20892.
Dr. Bennett's current address: Department of Neurology, Allegheny
University of the Health Sciences, Philadelphia, PA
19102.
REFERENCES
-
Bennett GJ,
Roberts WJ
(1996)
Animal models and their contribution to our understanding of complex regional pain syndromes I and II.
In: Reflex sympathetic dystrophy: a reappraisal. Progress in pain research and management, Vol 6
(Janïg, W,
Stanton-Hicks, M,
eds)
, p. 107. Seattle: IASP.
-
Blanchard J,
Ramamurthy S,
Walsh N,
Hoffman J,
Schoenfeld L
(1990)
Intravenous regional sympatholysis: a double blind comparison of guanethidine, reserpine, and normal saline.
J Pain Symptom Manage
6:357-361.
-
Bonica JJ
(1990)
Causalgia and other reflex sympathetic dystrophies.
In: The management of pain, 2nd ed
(Bonica, JJ,
eds)
, p. 220. Philadelphia: Lea & Febiger.
-
Bossut DF,
Perl ER
(1995)
Effects of nerve injury on sympathetic excitation of A
mechanical nociceptors.
J Neurophysiol
73:1721-1723 .
[Abstract/Free Full Text]
-
Davis KD,
Meyer RA,
Campbell JN
(1993)
Chemosensitivity and sensitization of nociceptive afferents that innervate the hairy skin of monkey.
J Neurophysiol
69:1071-1081 .
[Abstract/Free Full Text]
-
Drummond PD
(1995)
Noradrenaline increases hyperalgesia to heat in skin sensitized by capsaicin.
Pain
60:311-315 .
[ISI][Medline]
-
Dykes RW
(1984)
Central consequences of peripheral nerve injuries.
Ann Plast Surg
13:412-422 .
[ISI][Medline]
-
Gracely RH,
Lynch SA,
Bennett GJ
(1992)
Painful neuropathy: altered central processing maintained dynamically by peripheral input.
Pain
61:175-194.
-
Handwerker HO,
Kilo S,
Reeh RW
(1991)
Unresponsive afferent fibers in the sural nerve of the rat.
J Physiol (Lond)
435:229-242 .
[Abstract/Free Full Text]
-
Hu S,
Zhu J
(1989)
Sympathetic facilitation of sustained discharges of polymodal nociceptors.
Pain
38:85-89 .
[ISI][Medline]
-
Jänig W
(1990)
Activation of afferent fibers ending in an old neuroma by sympathetic stimulation in the rat.
Neurosci Lett
111:309-314 .
[ISI][Medline]
-
Kelly M
(1952)
Spread of sensory and motor loss after nerve injury.
Neurology
2:36-45.
-
Kim SH,
Chung JM
(1991)
Sympathectomy alleviates mechanical allodynia in an experimental animal model for neuropathy in the rat.
Neurosci Lett
134:131-134 .
[ISI][Medline]
-
Kinnman E,
Levine JD
(1995)
Involvement of the sympathetic postganglionic neuron in capsaicin-induced secondary hyperalgesia in the rat.
Neuroscience
65:283-291 .
[ISI][Medline]
-
Koltzenburg M,
Lundberg LER,
Torebjörk HE
(1992)
Dynamic and static components of mechanical hyperalgesia in human hairy skin.
Pain
51:207-219 .
[ISI][Medline]
-
Korenman EMD,
Devor M
(1981)
Ectopic adrenergic sensitivity in damaged peripheral nerve axons in the rat.
Exp Neurol
72:63-81.
[ISI][Medline]
-
LaMotte RH,
Shain CN,
Simone DA,
Tsai E-FP
(1991)
Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms.
J Neurophysiol
66:190-211 .
[Abstract/Free Full Text]
-
Levine JD,
Dardick SJ,
Basbaum AL,
Scipio E
(1985)
Reflex neurogenic inflammation. I. Contribution of the peripheral nervous system to spatially remote inflammatory responses that follow injury.
J Neurosci
5:1380-1386 .
[Abstract]
-
Levine JD,
Taiwo YO,
Collins SD,
Tam JK
(1986)
Noradrenaline hyperalgesia is mediated through interaction with sympathetic postganglionic neurone terminals rather than activation of primary nociceptors.
Nature
323:158-160 .
[Medline]
-
Liu M,
Max MB,
Robinovitz E,
Bennett GJ
(1995a)
Capsaicin-evoked allodynia: a study of three methods (abstract).
Anesthesiology
83:A863.
-
Liu M, Max MB, Robinovitz E, Kingery EB, Gracely RH, Bennett
GJ (1995b) Magnitude and variability of capsaicin-induced
pain, allodynia, and pinprick hyperalgesia on foot dorsum compared to
volar forearm, Am Pain Soc Meeting Abstracts A-38.
-
Loh L,
Nathan PW
(1978)
Painful peripheral states and sympathetic blocks.
J Neurol Neurosurg Psychiatry
41:664-671 .
[Abstract]
-
Marchettini P,
Lacerenza M,
Marangoni C,
Pellagat G,
Sotgiu ML,
Smirne S
(1992)
Lidocaine test in neuralgia.
Pain
48:377-382 .
[ISI][Medline]
-
Ochoa JL,
Verdugo RJ
(1995)
Reflex sympathetic dystrophy: a common clinical avenue for somatoform expression.
Neurol Clin
13:351-363 .
[ISI][Medline]
-
Park K,
Max MB,
Robinovitz E,
Gracely RH,
Bennett GJ
(1995)
Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects.
Pain
63:163-172 .
[ISI][Medline]
-
Raja SN,
Treede R-D,
Davis KD,
Campbell JN
(1991)
Systemic alpha-adrenergic blockade with phentolamine: a diagnostic test for sympathetically maintained pain.
Anesthesiology
74:691-698 .
[ISI][Medline]
-
Raja SN, Meleka SM, Turnquist JL, Campbell
JN (1994) Monitoring adequacy of
-adrenoreceptor blockade
following systemic phentolamine administration. Am Pain Soc Meeting
Abstracts 94A. -
Raja SN,
Turnquist JL,
Meleka S,
Campbell JN
(1996)
Monitoring adequacy of
-adrenergic blockade following systemic phentolamine administration.
Pain
64:197-204.
[ISI][Medline]
-
Roberts WJ
(1986)
A hypothesis on the physiological basis for causalgia and related pains.
Pain
24:297-311 .
[ISI][Medline]
-
Sang CN,
Gracely RH,
Max MB,
Bennett GJ
(1996)
Capsaicin-evoked mechanical allodynia and hyperalgesia cross nerve territories: evidence for a central mechanism.
Anesthesiology
85:491-496 .
[ISI][Medline]
-
Sato J,
Perl ER
(1991)
Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury.
Science
251:1608-1610 .
[Abstract/Free Full Text]
-
Sato J,
Suzuki S,
Iseki T,
Kumazawa T
(1993)
Adrenergic excitation of cutaneous nociceptors in chronically inflamed rats.
Neurosci Lett
164:225-228 .
[ISI][Medline]
-
Schmidt R,
Schmelz M,
Forster C,
Ringkamp M,
Torebjörk E,
Handwerker H
(1995)
Novel classes of responsive and unresponsive C nociceptors in human skin.
J Neurosci
15:333-341 .
[Abstract]
-
Simone DA,
Baumann TK,
LaMotte RH
(1989)
Dose-dependent pain and mechanical hyperalgesia after intradermal injection of capsaicin.
Pain
38:99-107 .
[ISI][Medline]
-
Torebjörk HE,
Lundberg LER,
LaMotte RH
(1992)
Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia in humans.
J Physiol (Lond)
448:765-780 .
[Abstract/Free Full Text]
-
Treede R,
Cole JD
(1993)
Dissociated secondary hyperalgesia in a subject with a large-fibre sensory neuropathy.
Pain
53:169-174 .
[ISI][Medline]
-
Verdugo RJ,
Ochoa JL
(1994)
Sympathetically maintained pain. I. Phentolamine block questions the concept.
Neurology
44:1003-1010 .
[Abstract/Free Full Text]
-
Verdugo RJ,
Campero M,
Ochoa JL
(1994)
Phentolamine sympathetic block in painful neuropathies. II. Further questioning of the concept of ``sympathetically maintained pain.
Neurology
44:1010-1014 .
[Abstract/Free Full Text]
-
Wall PD,
Gutnick M
(1974)
Ongoing activity in peripheral nerves: the physiology and pharmacology of impulses originating from a neuroma.
Exp Neurol
43:580-593 .
[ISI][Medline]
This article has been cited by other articles:

|
 |

|
 |
 
Y. Ren, X. Zou, L. Fang, and Q. Lin
Sympathetic Modulation of Activity in A{delta}- and C-Primary Nociceptive Afferents After Intradermal Injection of Capsaicin in Rats
J Neurophysiol,
January 1, 2005;
93(1):
365 - 377.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Lutgendorf, H. Logan, H. L. Kirchner, N. Rothrock, S. Svengalis, K. Iverson, and D. Lubaroff
Effects of Relaxation and Stress on the Capsaicin-Induced Local Inflammatory Response
Psychosom Med,
July 1, 2000;
62(4):
524 - 534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Elam, B. Olausson, J. O. Skarphedinsson1, and B. G. Wallin
Does sympathetic nerve discharge affect the firing of polymodal C-fibre afferents in humans?
Brain,
December 1, 1999;
122(12):
2237 - 2244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Ziegler, W. Magerl, R. A. Meyer, and R.-D. Treede
Secondary hyperalgesia to punctate mechanical stimuli: Central sensitization to A-fibre nociceptor input
Brain,
December 1, 1999;
122(12):
2245 - 2257.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. B. Max and I. Gilron
Sympathetically maintained pain
Neurology,
March 1, 1999;
52(5):
905 - 905.
[Full Text]
|
 |
|

|
 |

|
 |
 
R. Baron, G. Wasner, R. Borgstedt, E. Hastedt, H. Schulte, A. Binder, F. Kopper, M. Rowbotham, J. D. Levine, and H. L. Fields
Effect of sympathetic activity on capsaicin-evoked pain, hyperalgesia, and vasodilatation
Neurology,
March 1, 1999;
52(5):
923 - 923.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|